Citadel Advisors’s Annovis Bio ANVS Stock Holding History

Citadel Advisors’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$214K	Buy	114,800 +68,200	+146%	+$133K	﹤0.01%	11921
2026 Q1	$104K	Sell	46,600 -115,900	-71%	-$318K	﹤0.01%	11987
2025 Q4	$562K	Buy	162,500 +53,300	+49%	+$160K	﹤0.01%	8748
2025 Q3	$226K	Buy	109,200 +76,200	+231%	+$190K	﹤0.01%	10996
2025 Q2	$71.6K	Sell	33,000 -15,600	-32%	-$30.8K	﹤0.01%	11570
2025 Q1	$72.9K	Buy	48,600 +33,600	+224%	+$103K	﹤0.01%	11861
2024 Q4	$75.5K	Sell	15,000 -2,800	-16%	-$20.3K	﹤0.01%	11859
2024 Q3	$143K	Sell	17,800 -134,700	-88%	-$1.26M	﹤0.01%	10620
2024 Q2	$878K	Buy	152,500 +64,200	+73%	+$520K	﹤0.01%	6856
2024 Q1	$1.05M	Buy	88,300 +33,100	+60%	+$361K	﹤0.01%	6811
2023 Q4	$1.03M	Buy	+55,200	New	+$489K	﹤0.01%	6612

Other funds holding ANVS

EAM

Empery Asset Management New York $86.5M AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors's ANVS Position: Q2 2026 in Review

Citadel Advisors opened a new position in Annovis Bio (ANVS) in Q2 2026: 243,682 shares worth $453K. The stake represents ﹤0.01% of the portfolio and ranks #10102 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ANVS as recently as Q3 2025.

Citadel Advisors first reported a position in ANVS in Q1 2021 and has held it in 9 quarters since. The position peaked at $1.18M in Q3 2021. 61 funds tracked by Wall St. Rank hold ANVS as of Q2 2026.

Citadel Advisors held 243,682 shares of Annovis Bio worth $453K as of Q2 2026.
Annovis Bio was a new Citadel Advisors position in Q2 2026.
Annovis Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #10102 holding.
Citadel Advisors first reported a position in Annovis Bio in Q1 2021 and has held it in 9 quarters since.
Citadel Advisors's Annovis Bio position peaked at $1.18M in Q3 2021.
61 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.